Evidence map›Paper›PMID 15717202›Full record

ArticleHuman genetics2005

Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency.

Runa Njålsson, Ellinor Ristoff, Katarina Carlsson, Andreas Winkler, Agne Larsson, Svante Norgren

Abstract read
PubMed Publisher
In one paragraph

Article in Human genetics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Clinical feature and genetic analysis ofFrontiers in genetics · 2023
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Glutathione in Brain Disorders and Aging.Molecules (Basel, Switzerland) · 2022
    Review
  8. Article
  9. The glutathione cycle shapes synaptic glutamate activity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  10. Antioxidants in Personalized Nutrition and Exercise.Advances in nutrition (Bethesda, Md.) · 2018
    Review
  11. Article
  12. Article
  13. Article
  14. Glutathione is a physiologic reservoir of neuronal glutamate.Biochemical and biophysical research communications · 2011
    Article
  15. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Article
  16. Article
  17. Diagnosis of glutathione synthetase deficiency in newborn screening.Journal of inherited metabolic disease · 2009
    Article
  18. Article
  19. Inborn errors in the metabolism of glutathione.Orphanet journal of rare diseases · 2007
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Runa NjålssonDivision of Paediatrics, Department of Clinical Sciences, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm 14186, Sweden. runa.njalsson@mednut.ki.se
Ellinor Ristoff
Katarina Carlsson
Andreas Winkler
Agne Larsson
Svante Norgren
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutathione synthetase (GS) deficiency is a rare autosomal recessive disorder. The clinical phenotype varies widely, and nearly 30 different mutations in the GSS gene have been identified. In the present study, genotype, enzyme activity, metabolite levels and clinical phenotype were evaluated in 41 patients from 33 families. From some of the patients, data on glutathione (GSH) levels and gamma-glutamylcysteine levels in cultured fibroblasts were also available. Twenty-seven different mutations were found: 14 missense, 9 splice, 2 deletions, 1 insertion and 1 nonsense mutation. Twenty-three patients were homozygous and 18 were compound heterozygous. The moderate and severe clinical phenotypes could not be distinguished based on enzyme activity, GSH or gamma-glutamylcysteine levels in cultured fibroblasts. However, in fibroblasts, the residual GS activity was correlated with the GSH level. All mutations causing frameshifts, premature stop codons or aberrant splicing were associated with moderate or severe clinical phenotypes including haemolytic anaemia, 5-oxoprolinuria, and (in several forms) neurodevelopmental signs. The data indicate that additional genetic or environmental factors modify at least the moderate and severe phenotypes and that the clinical classification given to the patients may be influenced by variation in follow-up. The type of mutation involved can, to some extent, predict a mild versus a more severe phenotype.

Indexed as

Cells, CulturedDipeptidesFemaleFibroblastsGenotypeGlutathioneGlutathione SynthaseHumansMaleMutationPhenotypeDipeptidesgamma-glutamylcysteineGlutathioneGlutathione Synthase

Identifiers

PMID15717202
OpenAlexW2046948747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.